title: Therapeutic options for the management of pancreatic cancer.
abstract: Since its initial characterization, pancreatic ductal adenocarcinoma has remained one of the most devastating and difficult cancers to treat. Pancreatic cancer is the fourth leading cause of death in the United States, resulting in an estimated 38460 deaths annually. With few screening tools available to detect this disease at an early stage, 94% of patients will die within five years of diagnosis. Despite decades of research that have led to a better understanding of the molecular and cellular signaling pathways in pancreatic cancer cells, few effective therapies have been developed to target these pathways. Other treatment options have included more sophisticated pancreatic cancer surgeries and combination therapies. While outcomes have improved modestly for these patients, more effective treatments are desperately needed. One of the greatest challenges in the future of treating this malignancy will be to develop therapies that target the tumor microenvironment and surrounding pancreatic cancer stem cells in addition to pancreatic cancer cells. Recent advances in targeting pancreatic stellate cells and the stroma have encouraged researchers to shift their focus to the role of desmoplasia in pancreatic cancer pathobiology in the hopes of developing newer-generation therapies. By combining novel agents with current cytotoxic chemotherapies and radiation therapy and personalizing them to each patient based on specific biomarkers, the goal of prolonging a patient's life could be achieved. Here we review the most effective therapies that have been used for the treatment of pancreatic cancer and discuss the future potential of therapeutic options.
authors.affiliation: Maria L Rossi, Azeem A Rehman, Christopher S Gondi, Department of Medicine, University of Illinois College of Medicine-Peoria, Peoria, IL 61656-1649, United States.
authors.forename: Maria L
authors.initials: ML
authors.lastname: Rossi
authors.affiliation: Maria L Rossi, Azeem A Rehman, Christopher S Gondi, Department of Medicine, University of Illinois College of Medicine-Peoria, Peoria, IL 61656-1649, United States.
authors.forename: Azeem A
authors.initials: AA
authors.lastname: Rehman
authors.affiliation: Maria L Rossi, Azeem A Rehman, Christopher S Gondi, Department of Medicine, University of Illinois College of Medicine-Peoria, Peoria, IL 61656-1649, United States.
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Gondi
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D021441:Carcinoma, Pancreatic Ductal / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D019008:Drug Resistance, Neoplasm; D055088:Early Detection of Cancer; D006801:Humans; D020360:Neoadjuvant Therapy; D010180:Pancreatectomy / Q000009:adverse effects / Q000401:mortality; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016577:Pancreaticoduodenectomy / Q000009:adverse effects / Q000401:mortality; D011237:Predictive Value of Tests; D016896:Treatment Outcome
keywords: Adjuvant therapy; Chemotherapy; Microenvironment; Neoadjuvant therapy; Pancreatic cancer; Pancreatic cancer stem cells; Personalized therapy; Radiation; Surgical resection